iQone Healthcare Group is offering therapies that address blood cancer diseases.


The core mission of iQone Healthcare Group’s franchise in haemato-oncology is to bring innovative pharmaceutical products to patients in Europe.
Oncological and haematological cancers remain pressing challenges for modern medicine and constitutes one of the area of highest unmet medical needs. Today, innovative treatments are being developed that bring hope to patients around the world by targeting cancer cells with greater specificity and fewer side effects.
iQone Healthcare Group’s experience in pharmaceutical products reaches back 10+ years. Currently, our treatment is addressing an uncommon haemato-oncological disease.

Peripheral T-cell lymphomas (PTCLs) are aggressive types of non-Hodgkin lymphoma (NHL) that develop in white blood cells called “T cells” and “natural killer (NK) cells”. PTCLs generally affect people older than 60 years. T‐cell lymphomas make up between 10% and 15% of lymphoid malignancies.